1887

Abstract

Summary

The serum total IgG and IgG subclass and nasal wash IgA and IgG antibody responses of mice to influenza virus A/Hong Kong/68 (H3N2) subunit preparations administered parenterally as a single dose, incorporated either in immune stimulatory compounds (ISCOMs) or liposomes with Freund’s Complete Adjuvant, or as an aqueous material, as well as to live, infectious virus were measured by ELISA at 10 days and 3, 5, 7 and 22 weeks after immunisation. The protection of the upper and lower respiratory tracts provided by these preparations against homologous and heterologous challenge infection was assessed. Of the four variously-presented subunit preparations, influenza subunit ISCOMs induced relatively high and persisting levels of each of the different IgG subclasses, particularly IgG2a, throughout the study, and most nearly approached those observed after intranasal infection of mice with infectious virus. Furthermore, nasal wash IgA and IgG antibody levels, particularly at 5 or 7 weeks after immunisation, were also significantly greater in mice given the subunit ISCOM preparation than those induced by other subunit preparations with adjuvant or subunits given alone, and provided protection of both the upper and lower respiratory tracts against challenge as similar to that elicited by infectious virus.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-40-4-261
1994-04-01
2022-11-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/40/4/medmicro-40-4-261.html?itemId=/content/journal/jmm/10.1099/00222615-40-4-261&mimeType=html&fmt=ahah

References

  1. Potter CW. Inactivated influenza virus vaccines. Beare AS. Basic and applied influenza research Boca Raton, FL: CRC Press; 1982119–158
    [Google Scholar]
  2. Hobson D. Assessment of the efficacy of influenza vaccines against natural challenge. Perkins FT, Regamey RH, Hennessey W. International symposium on immunity to infections of the respiratory system in man and animalsDev Biol Stand 1975; 28:285–294
    [Google Scholar]
  3. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69–75
    [Google Scholar]
  4. Pickering JM, Smith H, Sweet C. Influenza virus pyrogenicity : central role of structural orientation of virion components and involvement of viral lipid and glycoproteins. J Gen Virol 1992; 73:1345–1354
    [Google Scholar]
  5. Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989; 160:191–198
    [Google Scholar]
  6. Bombord R. Immunomodulation by adjuvants. Dimmock NJ, Griffiths PD, Madeley CR. Control of virus diseases Cambridge: Cambridge University Press; 1990315–339
    [Google Scholar]
  7. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 1990; 11:89–97
    [Google Scholar]
  8. Tsujimoto M, Kotani S, Kinoshita F. Adjuvant activity of 6-0-acyl-muramyldipeptides to enhance primary cellular and humoral responses in guinea pigs: adaptability to various vehicles and pyrogenicity. Infect Immun 1986; 53:511–516
    [Google Scholar]
  9. Nerome K, Yoshioka Y, Ishida M. Development of a new type of influenza subunit vaccine made by muramyl-dipeptide-liposome : enhancement of humoral and cellular immune responses. Vaccine 1990; 8:503–509
    [Google Scholar]
  10. Lovgren K, Kaberg H, Morein B. An experimental influenza subunit vaccine (ISCOM): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin Exp Immunol 1990; 82:435–439
    [Google Scholar]
  11. Ben Ahmeida ETS, Jennings R, Erturk M, Potter CW. The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus. Arch Virol 1992; 125:71–86
    [Google Scholar]
  12. Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Channock RM. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun 1982; 36:1102–1108
    [Google Scholar]
  13. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23:66–72
    [Google Scholar]
  14. Crawford CR, Mukhlis FA, Jennings R, Oxford JS, Hockley DJ, Potter CW. Use of zwitterionic detergent for the preparation of an influenza virus vaccine. 1. Preparation and characterization of disrupted virions. Vaccine 1984; 2:193–198
    [Google Scholar]
  15. Wood JM, Schild GC, Newman RW, Seagrott V. Application for an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines. Perkins FT, Regamey RH. International symposium on influenza immunisation Dev Biol Stand 1977; 39:193–200
    [Google Scholar]
  16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248–254
    [Google Scholar]
  17. Gregoriadis G, Tan L, Ben-Ahmeida ETS, Jennings R. Lipo- somes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen. Vaccine 1992; 10:747–753
    [Google Scholar]
  18. Jennings R, Denton MD, Potter CW. The hamster as an experimental animal for the study of influenza. I. The role of antibody in protection. Med Microbiol Immunol 1976; 162:217–226
    [Google Scholar]
  19. Jennings R, Smith T, Potter CW. Use of the enzyme-linked immunosorbent assay (ELISA) for the estimation of serum antibodies in an influenza virus vaccine study. Med Microbiol Immunol 1981; 169:247–258
    [Google Scholar]
  20. Hocart MJ, Mackenzie JS, Stewart GA. The immunoglobulin G subclass responses of mice to influenza A virus : the effect of mouse strain, and the neutralizing abilities of individual protein-A-purified subclass antibodies. J Gen Virol 1989; 70:2439–2448
    [Google Scholar]
  21. Gross PA, Weksler ME, Quinnan GV, Douglas RG, Gaerlan PF, Denning CR. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987; 25:1763–1765
    [Google Scholar]
  22. Zuckerman M, Oxford J, Wood J, Taylor J. The influenza A (H3N2) component of recommended vaccine induces antibody to the current virus. Lancet 1990; 1:179–180
    [Google Scholar]
  23. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986; 154:121–127
    [Google Scholar]
  24. Edelman R. Vaccine adjuvants. Rev Infect Dis 1980; 2:370–383
    [Google Scholar]
  25. Potter CW, Jennings R, McLaren C. Immunity to influenza in ferrets. VI. Immunization with adjuvanted vaccines. Arch. fur die gesamte Virusforschung 1973; 42:285–296
    [Google Scholar]
  26. Ben Ahmeida ETS, Jennings R, Tan L, Gregoriadis G, Potter CW. The subclass IgG responses of mice to influenza surface proteins formulated into liposomes. Antiviral Res in press
    [Google Scholar]
  27. Spiegelberg HL. Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol 1974; 19:259–294
    [Google Scholar]
  28. Wiener E. The ability of IgG subclasses to cause the elimination of targets in vivo and to mediate their destruction by phagocytosis/cytolysis in vitro . Shakib F. The human IgG subclasses: molecular analysis of structure, function and regulation Oxford: Pergamon Press; 1990135–160
    [Google Scholar]
  29. Jones PD, Tha-Hla R, Morein B, Lovgren K, Ada GL. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatorycomplexes(ISCOMs). Scand J Immunol 1988; 27:645–652
    [Google Scholar]
  30. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990; 344:873–875
    [Google Scholar]
  31. Erturk M, Phillpotts RJ, Welch MJ, Jennings R. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection. Vaccine 1991; 9:728–734
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-40-4-261
Loading
/content/journal/jmm/10.1099/00222615-40-4-261
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error